Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4
- 1 December 2006
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 350 (4), 866-871
- https://doi.org/10.1016/j.bbrc.2006.09.097
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Toll-like receptor 2 controls expansion and function of regulatory T cellsJCI Insight, 2006
- Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerizationInternational Immunology, 2004
- Saturated Fatty Acid Activates but Polyunsaturated Fatty Acid Inhibits Toll-like Receptor 2 Dimerized with Toll-like Receptor 6 or 1Published by Elsevier BV ,2004
- Reciprocal Modulation of Toll-like Receptor-4 Signaling Pathways Involving MyD88 and Phosphatidylinositol 3-Kinase/AKT by Saturated and Polyunsaturated Fatty AcidsPublished by Elsevier BV ,2003
- Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunitExperimental & Molecular Medicine, 2003
- Inhibition of TPA-induced NF-κB nuclear translocation and production of NO and PGE2 by the anti-rheumatic gold compoundsJournal of Pharmacy and Pharmacology, 2003
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Inhibition of the DNA‐binding activity of NF‐κB by gold compounds in vitroFEBS Letters, 1995
- Aurothioglucose inhibits induced NF-kB and AP-1 activity by acting as an IL-1 functional antagonistBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1992